Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antigen Targeted In Therapy for Melanoma also Prompts Immune Response in Brain Tumor Cells

25.09.2003


A protein fragment that was previously found in melanomas has now been detected in highly aggressive brain tumors called gliomas that take the lives of about 15,000 Americans each year.

This peptide, which the immune system recognizes as an antigen, or foreign invader, appears to be a target for anti-tumor immune therapy, according to studies conducted by researchers at Cedars-Sinai’s Maxine Dunitz Neurosurgical Institute and the National Cancer Institute. It also may be useful as a marker that will enable scientists to monitor immune responses in human clinical trials against cancer cells called glioblastoma multiforme (GBM), often referred to as gliomas.

Institute scientists and neurosurgeons have for several years conducted clinical trials using immunotherapy techniques to battle gliomas, removing brain tumor cells and culturing them with immune system cells called dendritic cells in the lab. When the resulting "vaccine" is injected into the patient’s bloodstream, the dendritic cells recognize the tumor cells as invaders and "present" them to the antigen-fighting T-lymphocytes, triggering an immune response.



"The outlook for patients who suffer from these highly aggressive tumors has historically been extremely poor, and even conventional treatments such as surgery, chemotherapy and radiation therapy have provided almost no benefit," said Keith L. Black, M.D., neurosurgeon and founder and director of the Institute. "Based on the results of our early studies, the immune system appears to have the potential to destroy glioma cells and contribute to longer periods of patient survival. Unfortunately, the immune system is not very effective on its own. Therefore, we are always looking for new ways to target and boost the immune response."

In mouse and human studies of melanoma, tyrosinase-related protein-2 (TRP-2) has proved to be an excellent target for immunotherapies. This study found that the TRP-2 antigen also was expressed at significant levels in glioma cells and that a strong immune response could be triggered against it.

Tests were conducted on the genetic material of established glioma cell lines and on cells of brain tumors removed from patients undergoing treatment at the Maxine Dunitz Neurosurgical Institute. Lab results demonstrated that TRP-2 protein was expressed in primary cultured glioma cells and in fresh tissue.

Additional tests found that certain cytotoxic T lymphocytes - immune system cells that attack invaders - were able to recognize TRP-2 as a target when TRP-2 was expressed in significant levels. The degree of recognition correlated with the level of TRP-2 expression in the genetic material, an important finding because TRP-2 is expressed to lesser degrees - below the recognition and immune activation threshold - in normal brain tissue.

The researchers also were able to generate in the laboratory an immune response using blood cells and dendritic cells from a healthy donor and specially prepared TRP-2-positive glioma cells. The immune cells were able to recognize the TRP-2 positive GBM tumor cell lines, and an increase in TRP-2-specific antigen-killing activity could be seen. The identification of TRP-2 as a brain tumor-associated antigen appears, therefore, to offer not only a new target for immunotherapy, but a way to monitor related immune responses.

An increase in TRP-2-related immune activity also was detected in four patients with malignant brain tumors who were part of a clinical trial at the Maxine Dunitz Neurosurgical Institute. Cytotoxic T lymphocyte activity was significantly increased after three dendritic cell vaccinations, and the patients appeared to have no adverse effects from the vaccinations.

Research scientist Gentao Liu, Ph.D., was the paper’s first author. Other Institute contributors included research scientist Christopher J. Wheeler, Ph.D.; John S. Yu, M.D., co-director of the Comprehensive Brain Tumor Program; Dr. Black, who directs the medical center’s Division of Neurosurgery and the Comprehensive Brain Tumor Program and holds the Ruth and Lawrence Harvey Chair in Neuroscience; and research scientist Han Ying, Ph.D. Hung T. Khong, M.D., a contributing author from the Surgery Branch of the National Cancer Institute, was involved in previous discoveries of TRP-2 in melanoma.

Funding was provided in part by National Institutes of Health grant NS02232-01 to Dr. Yu.

Cedars-Sinai is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. Named one of the 100 "Most Wired" hospitals, the Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.

Sandy Van | Van Communications

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>